Last reviewed · How we verify
NCT04630574: TPMH
Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers
trial testing Speech evaluation with the clinical evaluation of dysarthria in Huntington Disease in 150 participants. Completed in 5 February 2024.
5 February 2024
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 23 February 2021 |
| Primary completion | 5 February 2024 |
| Estimated completion | 5 February 2024 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Speech evaluation with the clinical evaluation of dysarthria
- complete assessment of the MonPaGe computerized protocol
Conditions studied
- Huntington Disease — all drugs for Huntington Disease →
Sponsor
University Hospital, Bordeaux
Who can join
18 and older, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol. This tool is based on a multidimensional and quantified assessment of voice and speech, by a set of targeted acoustic and perceptual criteria.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04630574
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Huntington Disease
Currently open trials in the same condition.
- NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
- NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
- NCT06774443 — Hinting Task for Huntington's Disease · recruiting
- NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
- NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04630574 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 20 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630574.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing